Bolus Versus Continuous Remimazolam for Anesthetic Induction

Kangbuk Samsung Hospital62 enrolled

Overview

Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. Although it is known to cause less hemodynamic instability, the incidence hypotension is the one of the most frequent adverse events with its use. For anesthetic induction, remimazolam can be used either as bolus dose or as continuous infusion. This study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (12 mg/kg/hr) remimazolam administration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

TRIPLE

Enrollment

Conditions

Hypotension on Induction

Interventions

Remimazolam bolusDRUG

Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, \<40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, \>80 years

Remimazolam continuousDRUG

Remimazolam 12 mg/kg/hr

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * scheduled for elective surgery under general anesthesia * adult patient (over 19 years old) * American Society of Anesthesiology Physical Status I-III Exclusion Criteria: * arrythmia * liver dysfunction * kidney dysfunction * uncontrolled hypertension * uncontrolled diabetes mellitus * allergic to benzodiazepines * heart failure * drug intoxication * alcohol intoxication